Rossari Biotech Ltd Q1 FY2023 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/hyn520onxf5zgsm8k1ec60gh.pdf

Key Takeaways


Revenue Headwinds & Demand Environment

Chari: "We are also very cautious in terms of not entering into segments or not buying raw materials, it is better to forego sales, rather than set up sorry figure."

Margin Dynamics & Profitability

Sablok: "Given the current situation, I think question on steady state, our immediate medium-term target is to come back to our 14% - 15% kind of EBITDA margin and on a longer-term basis, I think we keep regiving our product portfolio. We aim to be 15% to 17% plus margin over the next year or two."

Acquired Companies: Unitop, Tristar & Romakk


New Product Pipeline & Innovation


Strategy & Capital Allocation Philosophy

Chari: "As a company now our focus will be on absolute amount of money, we would not look at percentage of EBITDA. Secondly, our focus would be on asset turns."

Guidance & Commitments

CommitmentSpecificsTimeline
FY23 EBITDA and PAT₹250 cr EBITDA, ₹150 cr PAT; may revisit after Q2FY23, with Q2 review point
Q2 FY23 revenueSimilar to Q1 FY23 levels (not vs abnormal Q2 FY22)Q2 FY23
H2 improvementNumbers anticipated to improve from H2 onwardH2 FY23
Unitop FY23 turnoverAt least ₹450–500 crFY23
Medium-term EBITDA marginReturn to 14–15%Medium-term
Longer-term EBITDA margin15–17%+ (internal target)Next year or two
Paint business Q2Higher sales expected vs Q1Q2 FY23
Pet food introductionFinalized for launchComing quarter
Animal health esters and glyceridesFinal stage of testing, introduction shortlyNear-term

Key Metrics

MetricQ1 FY23
Consolidated revenue from operations₹434.7 crore, vs ₹438.9 crore in Q4 FY22
Standalone revenue from operations₹233.73 crore, vs ₹261.64 crore in Q4 FY22; +15% YoY
HPPC revenue₹316.5 crore, 73% of total revenue
Textile business revenue₹93.9 crore, 21% of total revenue
AHN revenue₹24.3 crore, 6% of total revenue
Consolidated EBITDA₹57.7 crore, vs ₹52.3 crore in Q4 FY22
Consolidated EBITDA margin13.3%, vs 11.9% in Q4 FY22
Consolidated PAT₹28.7 crore, vs ₹24.1 crore in Q4 FY22
Standalone EBITDA₹27.1 crore, vs ₹27.5 crore in Q4 FY22
Standalone EBITDA margin11.6%, vs 10.5% in Q4 FY22
Standalone PAT₹15.4 crore, vs ₹16.9 crore in Q4 FY22
Gross margin QoQ change+246 bps
EBITDA QoQ change+136 bps
Depreciation₹15.3 crore, higher owing to amortization of fair valuation on consolidation of subsidiaries
Interest costs₹5.1 crore
Unitop Q1 FY23 revenue~₹150 crore, out of ~₹200 crore revenue difference between standalone and consolidated
Unitop expected FY23 turnoverat least ₹450–500 crore
FY23 EBITDA guidance₹250 crore (reiterated)
FY23 PAT guidance₹150 crore (reiterated)
Standalone HPPC QoQ growth8% degrowth QoQ, 10% growth over Q1 FY22
Textile business gross margin improvementmore than 300 bps
Medium-term EBITDA margin target14% to 15%
Longer-term internal EBITDA margin target15% to 17% plus, over next year or two
Unitop Agro share of Unitop sales60% to 65%
Sanitizer sales vs prior levels~10% or less of earlier sales
Exhibition spend in Q1~₹2 crore
Tristar phenoxy propanol Reach Registration spend₹1 crore
Consolidated purchase of stock in trade~₹18 crore